Laboratory of America Holdings (LH) Touches $171.64 High on Jan, 14; 2 Bullish Analysts Covering Entercom Communications Corp. (ETM)

January 14, 2018 - By Adrian Mccoy

Among 3 analysts covering Entercom Communications (NYSE:ETM), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Entercom Communications had 5 analyst reports since August 18, 2015 according to SRatingsIntel. On Monday, November 27 the stock rating was maintained by Noble Financial with “Buy”. On Tuesday, August 18 the stock rating was upgraded by Wells Fargo to “Outperform”. The firm earned “Buy” rating on Monday, July 24 by Noble Financial. The company was maintained on Monday, July 31 by Noble Financial. Stephens initiated Entercom Communications Corp. (NYSE:ETM) rating on Friday, December 11. Stephens has “Equal-Weight” rating and $12 target. See Entercom Communications Corp. (NYSE:ETM) latest ratings:

27/11/2017 Broker: Noble Financial Rating: Buy Maintain
31/07/2017 Broker: Noble Financial Rating: Buy Maintain
24/07/2017 Broker: Noble Financial Rating: Buy Maintain

The stock of Laboratory Corporation of America Holdings (NYSE:LH) reached all time high today, Jan, 14 and still has $187.09 target or 9.00% above today’s $171.64 share price. This indicates more upside for the $17.47B company. This technical setup was reported by Barchart.com. If the $187.09 PT is reached, the company will be worth $1.57 billion more. The stock increased 0.80% or $1.36 during the last trading session, reaching $171.64. About 499,970 shares traded. Laboratory Corporation of America Holdings (NYSE:LH) has risen 10.51% since January 14, 2017 and is uptrending. It has underperformed by 6.19% the S&P500.

Investors sentiment increased to 1.5 in 2017 Q3. Its up 0.35, from 1.15 in 2017Q2. It increased, as 15 investors sold Entercom Communications Corp. shares while 23 reduced holdings. 25 funds opened positions while 32 raised stakes. 25.83 million shares or 18.66% more from 21.77 million shares in 2017Q2 were reported. Natl Bank Of Mellon Corporation owns 322,408 shares or 0% of their US portfolio. Kirr Marbach And Ltd Limited Liability Company In has 0.09% invested in Entercom Communications Corp. (NYSE:ETM). Ameritas Ptnrs Incorporated holds 0% or 2,183 shares. Millennium Management Ltd Liability Corporation has invested 0% of its portfolio in Entercom Communications Corp. (NYSE:ETM). Schwab Charles Mgmt Incorporated reported 115,438 shares. Wells Fargo And Co Mn reported 80,615 shares. Raymond James has 93,472 shares for 0% of their portfolio. Geode Cap Management Ltd Liability has invested 0% in Entercom Communications Corp. (NYSE:ETM). Cheyne Capital Mgmt (Uk) Llp holds 0.41% or 4,305 shares in its portfolio. Alpine Management Lc has invested 0.17% of its portfolio in Entercom Communications Corp. (NYSE:ETM). Morgan Stanley reported 122,971 shares or 0% of all its holdings. D E Shaw Inc holds 0% of its portfolio in Entercom Communications Corp. (NYSE:ETM) for 42,074 shares. Ameriprise reported 14,638 shares stake. Denali Advisors Ltd Liability Corp owns 0% invested in Entercom Communications Corp. (NYSE:ETM) for 193 shares. Jpmorgan Chase And accumulated 4.38M shares.

The stock increased 1.34% or $0.15 during the last trading session, reaching $11.35. About 2.47M shares traded. Entercom Communications Corp. (NYSE:ETM) has declined 15.65% since January 14, 2017 and is downtrending. It has underperformed by 32.35% the S&P500.

Entercom Communications Corp. operates as a radio broadcasting firm in the United States. The company has market cap of $1.59 billion. The firm owns and operates radio stations in various formats, such as news, sports, talk, classic rock, urban, adult contemporary, alternative, country, and others. It has a 42.99 P/E ratio. As of February 22, 2017, it had 126 stations in 28 markets.

Since August 1, 2017, it had 0 buys, and 7 sales for $14.75 million activity. On Friday, August 11 the insider Williams R Sanders sold $486,338. On Friday, August 25 EBERTS F SAMUEL III sold $4.89 million worth of Laboratory Corporation of America Holdings (NYSE:LH) or 31,500 shares. The insider Gilliland Dwight Gary sold $149,068. Another trade for 2,871 shares valued at $459,739 was sold by Dodson Edward T. 5,000 Laboratory Corporation of America Holdings (NYSE:LH) shares with value of $800,000 were sold by Uthgenannt Lisa J. KING DAVID P had sold 44,687 shares worth $7.01 million on Wednesday, September 6. EISENBERG GLENN A had sold 5,968 shares worth $951,672.

Among 19 analysts covering Laboratory Corp (NYSE:LH), 10 have Buy rating, 0 Sell and 9 Hold. Therefore 53% are positive. Laboratory Corp had 49 analyst reports since July 29, 2015 according to SRatingsIntel. As per Tuesday, December 8, the company rating was downgraded by Goldman Sachs. The firm has “Overweight” rating by Barclays Capital given on Tuesday, April 26. The rating was downgraded by Zacks to “Buy” on Monday, August 17. The rating was maintained by Jefferies on Friday, November 24 with “Hold”. SunTrust maintained the stock with “Buy” rating in Thursday, January 11 report. The stock has “Neutral” rating by Mizuho on Friday, February 17. The stock has “Hold” rating by Mizuho on Friday, December 1. The firm has “Buy” rating given on Thursday, May 25 by Credit Suisse. The rating was maintained by Morgan Stanley on Thursday, August 10 with “Overweight”. The rating was maintained by Canaccord Genuity on Tuesday, April 26 with “Buy”.

Investors sentiment decreased to 0.9 in 2017 Q3. Its down 0.16, from 1.06 in 2017Q2. It fall, as 41 investors sold Laboratory Corporation of America Holdings shares while 239 reduced holdings. 70 funds opened positions while 181 raised stakes. 91.79 million shares or 1.82% less from 93.49 million shares in 2017Q2 were reported. Mirae Asset Global Ltd holds 0.04% of its portfolio in Laboratory Corporation of America Holdings (NYSE:LH) for 12,847 shares. Qs Investors Ltd Liability has 0.01% invested in Laboratory Corporation of America Holdings (NYSE:LH) for 4,408 shares. Sawgrass Asset Mngmt owns 224,897 shares. First Manhattan reported 28,742 shares. Moreover, Clinton Inc has 0.36% invested in Laboratory Corporation of America Holdings (NYSE:LH). Gateway Invest Advisers Limited Liability invested in 0.01% or 6,471 shares. Private Advisor Grp Inc Lc accumulated 0.01% or 3,229 shares. Winslow Evans & Crocker holds 0.36% or 7,174 shares. Diversified Tru Company invested in 2,027 shares or 0.02% of the stock. Greenleaf stated it has 0% in Laboratory Corporation of America Holdings (NYSE:LH). Ameriprise Fincl Inc invested in 88,233 shares or 0.01% of the stock. Ontario Teachers Pension Plan Board stated it has 0.07% in Laboratory Corporation of America Holdings (NYSE:LH). Gabelli Funds Lc, New York-based fund reported 49,200 shares. Cubic Asset Mgmt Ltd Company invested 0.26% of its portfolio in Laboratory Corporation of America Holdings (NYSE:LH). Principal Group holds 0.04% or 272,775 shares.

Analysts await Laboratory Corporation of America Holdings (NYSE:LH) to report earnings on February, 15. They expect $2.40 earnings per share, up 11.63% or $0.25 from last year’s $2.15 per share. LH’s profit will be $244.32M for 17.88 P/E if the $2.40 EPS becomes a reality. After $2.46 actual earnings per share reported by Laboratory Corporation of America Holdings for the previous quarter, Wall Street now forecasts -2.44% negative EPS growth.

Laboratory Corporation of America Holdings operates as an independent clinical laboratory firm worldwide. The company has market cap of $17.47 billion. It operates through two divisions, LabCorp Diagnostics and Covance Drug Development. It has a 23.94 P/E ratio. The firm offers a range of clinical laboratory tests and procedures, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C, PSA, tests for sexually-transmitted diseases, HCV tests, vitamin D, microbiology cultures and procedures, and alcohol and other substance-abuse tests that are used by hospitals, physicians and other healthcare providers and commercial clients to assist in the diagnosis, monitoring and treatment of diseases and medical conditions through the examination of substances in blood, tissues, and other specimens.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>